Pfizer, Sanofi record double-digit Q3 sales jumps; Novavax RSV candidate cuts infection by 50% in PhII;

> Pfizer's ($PFE) Q3 vaccines revenue reached $1.14 billion, a 19% increase over the year-ago period. Release (PDF)

> Strong flu vaccine performance and a Pentacel supply recovery drove an 11.2% vaccine revenue increase in Sanofi's ($SNY) third quarter. Release (PDF)

> In a Phase II trial of Novavax's ($NVAX) RSV F-protein vaccine, women who received the vaccine had a 50% reduction in infection. Release

> Germany's ImevaX GmbH, a specialist in vaccines against pathogens of chronic infectious diseases, has wrapped a $9.5 million Series A financing round to develop a vaccine against H. pylori. Release

> Vaccine maker Serum Institute of India says it will invest about $163 million for a new facility in its home country. More

> Israel's BiondVax has won patents in the EU and Japan for its universal flu vaccine. More

And Finally... The global halal vaccine market could be valued at approximately $1.1 billion by 2030 if the market taps into its full consumer base, an expert says. Report

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.